Excalipoint has successfully raised $68.7 million to further its development of T-cell engagers, a promising area in biotechnology. This funding comprises a $41 million seed round initiated at the company’s launch in August 2025, which was subsequently followed by a $27.7 million extension round just six months later.
The seed round was co-led by Hongshan Capital, Apricot Capital, and Yuanbio Venture Capital, with participation from a consortium of domestic investors. The extension round saw additional investments led by MPCi and Centurium Capital, with contributions from Lilly Asia Ventures and the Eisai Innovation Fund.
Central to Excalipoint’s investment strategy is a multi-platform approach to T-cell engagers. Instead of focusing on a singular lead asset, the company is developing approximately three distinct platforms: TOPAbody, T-Cell Immune Shield, and TCE Probody.
“Our focus is driven by where we believe T-cell-based therapies can create the greatest impact, both scientifically and clinically,” noted Lei Fang, CEO of Excalipoint Therapeutics, in a recent conversation with BioXconomy.
Fang identified three significant biological barriers that have hindered the success of T-cell engagers in clinical settings: insufficient T-cell activation, an immunosuppressive tumour microenvironment, and the limited number of targetable tumour-associated antigens.
In response to these challenges, the biotech firm has established a pipeline consisting of six programmes, which the recent financing will help to advance. “The $68.7 million financing will support the advancement of Excalipoint’s proprietary T-cell engager platforms and the expanding pipeline of differentiated programmes. First, we aim to advance our clinical development programmes, including the ongoing Phase I/II study of our lead programme, EXP011,” Fang elaborated.
Furthermore, the funding will facilitate the expansion and advancement of their multi-specific T-cell engager programmes across both oncology and immunology. Additionally, investments will be directed towards the development of technology platforms that enable the design of differentiated TCE therapies.
Excalipoint’s growth illustrates the increasing significance of China’s ‘NewCo’ biotech model, previously reported by BioXconomy. “Excalipoint is built on a capital-efficient NewCo model in China that combines experienced founders, differentiated science, efficient execution, and robust venture support. Our strategy is to rapidly generate meaningful clinical data while advancing a diversified pipeline across oncology and immunology,” Fang explained.
As the programmes continue to progress, the company anticipates pursuing future financing through a blend of additional private capital, strategic partnerships, and global collaborations. The current investor base forms a strong foundation as Excalipoint strives to establish itself as a globally competitive biotechnology entity.
Fang concluded, “Our goal is to generate meaningful clinical data while building a diversified pipeline that creates multiple opportunities for innovation and partnerships.”